Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 804 results for "sandoz inc"

Momenta Pharmaceuticals Announces Launch of Glatopa(TM) (glati...

CAMBRIDGE, Mass., June 18, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. ( Nasdaq:MNTA ), today announced that Sandoz has initiated its U.S. launch of once daily Glatopa (glatiramer acetate injection), a generic equivalent of daily COPAXONE ... BioSpace, 2 weeks ago
[x]  

4 images for sandoz inc

MSN News US, 3 weeks ago
Maryland Gazette, 2 months ago
NewsReality.com, 3 months ago
Livemint.com, 5 months ago
MSN News US

Sandoz recalls over 1 lakhs India-made anti-allergic tablets in US

A screen grab of Sandoz website. New Delhi: Drug firm Sandoz Inc is recalling India-made 1,023,430 units of anti-allergic Cetirizine HCl chewable tablets in the US due to impurity concerns. According to information on the USFDA site, the ...
 Livemint.com3 weeks ago Sandoz Inc Recalls India-Made Anti-Allergic Tablets In U.S.  Silicon India3 weeks ago
[x]  

Radiant Insights: Sandoz Inc. - Product Pipeline Review - 2014

Sandoz Inc. - Product Pipeline Review - 2014 Summary Global Market Direct's pharmaceuticals report, "Sandoz Inc. - Product Pipeline Review - 2014" (http://www.radiantinsights.com/research/sandoz-inc-product-pipeline-review-2014) provides data on ...
 Bloomberg3 weeks ago Sandoz Inc. - Product Pipeline Review - 2014  Individual.com3 weeks ago

Novartis tries to get U.S. ban lifted on sale of Neupogen copycat

WASHINGTON, June 3 In October, Amgen Inc, maker of the $1.2 billion-a-year drug Neupogen, sued Sandoz in district court in San Francisco, saying Zarxio infringed the patent on Amgen's drug. The court refused to grant a preliminary injunction ...
 Reuters1 month ago Novartis tries to get US ban lifted on sale of Neupogen copycat  Channel NewsAsia1 month ago
[x]  
TheStreet.com

Anacor Pharmaceuticals Announces Amendment to KERYDIN Commercialization Agreement

Anacor Pharmaceuticals, Inc. today announced an amendment to its distribution and commercialization agreement with Sandoz Inc., a Novartis company, pursuant to which PharmaDerm, the branded dermatology division of Sandoz, distributes and ...
 Yahoo! Canada1 week ago Anacor Pharmaceuticals, Inc. (ANAC) Announces Amendment To KERYDIN Commercialization Agreement 6/29/2015  ClinicSpace6 days ago Anacor Pharmaceuticals, Inc. Announces Amendment To KERYDIN Commercialization Agreement  BioSpace6 days ago Anacor Pharmaceuticals Names Graeme Bell as New Executive Vice President and Chief Financial Officer  Yahoo! UK and Ireland1 month ago
[x]  

Momenta Gains on Generic Copaxone's Launch in U.S.

Momenta Pharmaceuticals, Inc. ( MNTA - Analyst Report ) announced that its partner Sandoz (a Novartis ( NVS - Analyst Report ) Company) has initiated the launch of once-daily Glatopa, the first generic version of Teva Pharmaceuticals ( TEVA - ...
 Zacks.com2 weeks ago
[x]  

The Federal Circuit's First Foray into the BPCIA: A Pulitzer Prize for Complexity?

Yesterday, a Federal Circuit panel comprising Judges Newman, Lourie, and Chen heard oral argument in Amgen Inc. v. Sandoz Inc . (Fed. Cir. No. 2015-1499), the first ever case requiring the Appeals Court to address the meaning of various provisions ...
 National Law Review1 month ago BPCIA: A Choose Your Own Adventure Statute?  JD Supra2 weeks ago IP Update: Amgen v. Sandoz: The Oral Argument  Noodls1 month ago Federal Circuit Review | May 2015  JD Supra1 month ago
[x]  

Teva Standard of Review Becomes Outcome-Determinative in Fed. Circuit Ruling Last Week

Earlier this year in Teva Pharmaceuticals USA v. Sandoz, Inc. , 135 S. Ct. 831 (2015), the Supreme Court changed the appellate standard of review for claim construction decisions. The Court held that while claim construction is a legal question ...
 JD Supra3 days ago First Round of Post-Teva Claim Construction Decisions: Business as Usual?  JD Supra4 days ago

Motivation to Combine Reviewable for Clear Error - Insite Vision Inc. v. Sandoz, Inc.

Reviewing the district court's framing of the obviousness inquiry and determination of no motivation to combine for clear error, the U.S. Court of Appeals for the Federal Circuit affirmed the district court's determination upholding the ...
 JD Supra1 month ago

Premarket Biotech Digest: Gilead Files TAF NDA, Pristiq Goes Generic, Biocept Surges 7%

Jul. 2, 2015 9:08 AM ET | About: Gilead Sciences, Inc. (GILD), Includes: GSK, MRK, MYL, TEVA by: Kanak Kanti De Summary Gilead files third NDA for its TAF product, battling ViiV's Triumeq. Pristiq generics from Mylan and others get ...
 Seeking Alpha4 days ago Premarket Biotech Digest: Celgene-Juno, AbbVie Rx Data, FDA-Gilead Lawsuit  Seeking Alpha6 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less